Oncology / Haematology

A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Trial Name: RELATIVITY-104

PI: Dr Emma Beardsley

 

Who can take part:

• Patients with Histologically confirmed metastatic NSCLC of SQ or NSQ histology with Stage IV A/B (as defined by the 8th International Association for the Study of Lung Cancer Classification) or recurrent disease following multi-modal therapy for locally advanced disease.
• No prior systemic anti-cancer treatment (including EGFR and ALK inhibitors) given as primary therapy for advanced or metastatic disease

Exclusion criteria:

• Participants with untreated CNS metastases.
• EGFR mutations which are sensitive to available targeted inhibitor therapy are excluded
• ALK translocations which are sensitive to available targeted inhibitor therapy are excluded.
• ROS-1 translocations which are sensitive to available targeted inhibitor therapy are excluded.
• Known BRAFV600E mutations which are sensitive to available targeted inhibitor therapy are excluded.

For further information please contact Theresa – 9784 8562

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4